Business
HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
MIAMI, September 24, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be featured as part of the Presidential Symposium at the European Society for Medical Oncology 2025 Congress (ESMO 2025) which takes place from October
About this update from Akeso, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":292,"url":"https://media.zenfs.com/en/business-wire.com/2deb1a0f2a6531bf72a0f65525127a62"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xW1k9dnwu2ii.WggBdFoIw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU4NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2deb1a0f2a6531bf72a0f65525127a62","width":480,"height":292}},"lazy":false},{"type":"text","content":"Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC","length":293,"tagName":"p","attribs":{}},{"type":"text","content":"MIAMI, September 24, 2025--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be featured as part of the Presidential Symposium at the European Society for Medical Oncology 2025 Congress (ESMO 2025) which takes place from October 17–21, 2025, in Berlin, Germany. The presentation will take place on Sunday, October 19 during the Presidential Symposium from 4:30pm – 6:30pm CET (10:30am – 12:30pm EDT).","length":718,"tagName":"p"},{"type":"text","content":"HARMONi-6 is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, a PD-1 inhibitor, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) irrespective of PD-L1 expression. HARMONi-6 is a single region, multi-center, Phase III study conducted in China sponsored by Akeso with all relevant data exclusively generated, managed, and analyzed by Akeso.","length":479,"tagName":"p"},{"type":"text","content":"On April 23, 2025, Akeso announced, via a press release, topline results from HARMONi-6. At a prespecified interim analysis conducted by an Independent Data Monitoring Committee, ivonescimab pl...